Today's Breaking News
- Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
- Incyte Drug Jakafi (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
- Gilead Announces Interim Phase 2 Data for Idelalisib Showing Response in Refractory Indolent Non-Hodgkin’s Lymphoma
Latest R&D and Business News
- Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013
- MannKind Completes Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes
- Transition Therapeutics Announces Exercise of TT-401 Rights by Lilly
- Array BioPharma Announces Positive Interim Results From Combination Trial Of ARRY-520 With Kyprolis At The 2013 European Hematology Association Congress
- AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
- Acetylon Pharmaceuticals Presents Encouraging Safety and Clinical Response Data from Ongoing Clinical Trials of ACY-1215 for the Treatment of Multiple Myeloma
- Updated Results from Geron's Imetelstat Phase 2 Proof-of-Concept Trial in Essential Thrombocythemia Presented at the European Hematology Association Congress
- New long-term data reinforce safety profile of Pradaxa for stroke prevention in AF
- Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
- Ambrx and Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx's Antibody Drug Conjugate for Breast Cancer
- CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
- Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma